{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:09:02Z","timestamp":1770692942004,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"DOI":"10.1186\/s13018-025-06344-4","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:51:25Z","timestamp":1761742285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing prognostic precision: exploring the role of lung immune prognostic index in immunotherapy-treated soft tissue sarcoma patients\u2014a retrospective study"],"prefix":"10.1186","volume":"20","author":[{"given":"Minghao","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yitian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minxun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"3","key":"6344_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3322\/caac.21605","volume":"70","author":"AC Gamboa","year":"2020","unstructured":"Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200\u201329. https:\/\/doi.org\/10.3322\/caac.21605.","journal-title":"CA Cancer J Clin"},{"key":"6344_CR2","unstructured":"Fletcher C, Mertens F. WHO classification of tumours of soft tissue and bone: WHO classification of tumours, vol. 5: World Health Organization 2013."},{"issue":"7","key":"6344_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","volume":"20","author":"M von Mehren","year":"2022","unstructured":"von Mehren M, Kane JM, Agulnik M, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(7):815\u201333. https:\/\/doi.org\/10.6004\/jnccn.2022.0035.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"6344_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/13543784.2022.2152324","volume":"31","author":"E Cojocaru","year":"2022","unstructured":"Cojocaru E, Napolitano A, Fisher C, et al. What\u2019s the latest with investigational drugs for soft tissue sarcoma? Expert Opin Investig Drugs. 2022;31(11):1239\u201353. https:\/\/doi.org\/10.1080\/13543784.2022.2152324.","journal-title":"Expert Opin Investig Drugs"},{"key":"6344_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8926598","volume":"2018","author":"S Marshall","year":"2018","unstructured":"Marshall S, Nakano K, Sugiura Y, et al. Outcome for advanced or metastatic soft tissue sarcoma of nonextremities treated with doxorubicin-based chemotherapy: a retrospective study from a single cancer institution. Sarcoma. 2018;2018:8926598. https:\/\/doi.org\/10.1155\/2018\/8926598.","journal-title":"Sarcoma"},{"key":"6344_CR6","doi-asserted-by":"publisher","first-page":"1199292","DOI":"10.3389\/fphar.2023.1199292","volume":"14","author":"Z Tian","year":"2023","unstructured":"Tian Z, Yao W. Chemotherapeutic drugs for soft tissue sarcomas: a review. Front Pharmacol. 2023;14:1199292. https:\/\/doi.org\/10.3389\/fphar.2023.1199292.","journal-title":"Front Pharmacol"},{"key":"6344_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975986","volume":"13","author":"P Fang","year":"2022","unstructured":"Fang P, Zhou J, Liang Z, et al. Immunotherapy resistance in esophageal cancer: possible mechanisms and clinical implications. Front Immunol. 2022;13:975986. https:\/\/doi.org\/10.3389\/fimmu.2022.975986.","journal-title":"Front Immunol"},{"key":"6344_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948647","volume":"13","author":"X Jin","year":"2022","unstructured":"Jin X, Liu Z, Yang D, et al. Recent progress and future perspectives of immunotherapy in advanced gastric cancer. Front Immunol. 2022;13:948647. https:\/\/doi.org\/10.3389\/fimmu.2022.948647.","journal-title":"Front Immunol"},{"key":"6344_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","volume":"500","author":"C Chen","year":"2021","unstructured":"Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.024.","journal-title":"Cancer Lett"},{"issue":"14","key":"6344_CR10","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.7150\/thno.72800","volume":"12","author":"M Panagi","year":"2022","unstructured":"Panagi M, Pilavaki P, Constantinidou A, et al. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. Theranostics. 2022;12(14):6106\u201329. https:\/\/doi.org\/10.7150\/thno.72800.","journal-title":"Theranostics"},{"issue":"11","key":"6344_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/s1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501. https:\/\/doi.org\/10.1016\/s1470-2045(17)30624-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"6344_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/s1470-2045(18)30006-8","volume":"19","author":"SP D'Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416\u201326. https:\/\/doi.org\/10.1016\/s1470-2045(18)30006-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"6344_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00513-5","volume":"11","author":"CS Yiong","year":"2023","unstructured":"Yiong CS, Lin TP, Lim VY, et al. Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation? Biomark Res. 2023;11(1):75. https:\/\/doi.org\/10.1186\/s40364-023-00513-5.","journal-title":"Biomark Res"},{"key":"6344_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.753187","volume":"8","author":"LP Orellana Garc\u00eda","year":"2021","unstructured":"Orellana Garc\u00eda LP, Ehmann F, Hines PA, et al. Biomarker and companion diagnostics-a review of medicinal products approved by the European Medicines Agency. Front Med (Lausanne). 2021;8:753187. https:\/\/doi.org\/10.3389\/fmed.2021.753187.","journal-title":"Front Med (Lausanne)"},{"key":"6344_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejca.2022.08.023","volume":"176","author":"M Moehler","year":"2022","unstructured":"Moehler M, H\u00f6gner A, Wagner AD, et al. Recent progress and current challenges of immunotherapy in advanced\/metastatic esophagogastric adenocarcinoma. Eur J Cancer. 2022;176:13\u201329. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.023.","journal-title":"Eur J Cancer"},{"issue":"1","key":"6344_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/jco.2017.74.9846","volume":"36","author":"T Doi","year":"2018","unstructured":"Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody Pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36(1):61\u20137. https:\/\/doi.org\/10.1200\/jco.2017.74.9846.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6344_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE de Visser","year":"2006","unstructured":"de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24\u201337. https:\/\/doi.org\/10.1038\/nrc1782.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"6344_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.23736\/s1824-4785.20.03250-1","volume":"64","author":"JC Benitez","year":"2020","unstructured":"Benitez JC, Recondo G, Rassy E, et al. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. Q J Nucl Med Mol Imaging. 2020;64(2):162\u201374. https:\/\/doi.org\/10.23736\/s1824-4785.20.03250-1.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"6344_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cca.2018.04.023","volume":"483","author":"B Li","year":"2018","unstructured":"Li B, Zhou P, Liu Y, et al. Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis. Clin Chim Acta. 2018;483:48\u201356. https:\/\/doi.org\/10.1016\/j.cca.2018.04.023.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"6344_CR20","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.21873\/anticanres.13905","volume":"39","author":"T Nakamura","year":"2019","unstructured":"Nakamura T, Asanuma K, Hagi T, et al. Is serum lactate dehydrogenase useful for predicting oncological outcome in patients with soft tissue sarcoma? Anticancer Res. 2019;39(12):6871\u20135. https:\/\/doi.org\/10.21873\/anticanres.13905.","journal-title":"Anticancer Res"},{"issue":"4","key":"6344_CR21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.surg.2020.06.017","volume":"168","author":"EA Strong","year":"2020","unstructured":"Strong EA, Park SH, Ethun CG, et al. High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. Surgery. 2020;168(4):760\u20137. https:\/\/doi.org\/10.1016\/j.surg.2020.06.017.","journal-title":"Surgery"},{"key":"6344_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/jhc.S277453","volume":"7","author":"S Chen","year":"2020","unstructured":"Chen S, Huang Z, Jia W, et al. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced hepatocellular carcinoma patients treated with PD-1 inhibitors. J Hepatocell Carcinoma. 2020;7:289\u201399. https:\/\/doi.org\/10.2147\/jhc.S277453.","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"6344_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.amjsurg.2014.10.021","volume":"210","author":"J Szkandera","year":"2015","unstructured":"Szkandera J, Gerger A, Liegl-Atzwanger B, et al. The derived neutrophil\/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients. Am J Surg. 2015;210(1):111\u20136. https:\/\/doi.org\/10.1016\/j.amjsurg.2014.10.021.","journal-title":"Am J Surg"},{"issue":"3","key":"6344_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4771.","journal-title":"JAMA Oncol"},{"key":"6344_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003536","author":"JV Alessi","year":"2021","unstructured":"Alessi JV, Ricciuti B, Alden SL, et al. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003536.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"6344_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan Q, Weng D, Liu J, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023;4(8):101133. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101133.","journal-title":"Cell Rep Med"},{"issue":"Suppl 1","key":"6344_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3747\/co.27.5407","volume":"27","author":"O Ayodele","year":"2020","unstructured":"Ayodele O, Razak ARA. Immunotherapy in soft-tissue sarcoma. Curr Oncol. 2020;27(Suppl 1):17\u201323. https:\/\/doi.org\/10.3747\/co.27.5407.","journal-title":"Curr Oncol"},{"key":"6344_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejca.2021.04.034","volume":"152","author":"M Saerens","year":"2021","unstructured":"Saerens M, Brusselaers N, Rottey S, et al. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: a systematic review and meta-analysis. Eur J Cancer. 2021;152:165\u201382. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.034.","journal-title":"Eur J Cancer"},{"key":"6344_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775761","volume":"12","author":"M Roulleaux Dugage","year":"2021","unstructured":"Roulleaux Dugage M, Nassif EF, Italiano A, et al. Improving immunotherapy efficacy in soft-tissue sarcomas: a biomarker driven and histotype tailored review. Front Immunol. 2021;12:775761. https:\/\/doi.org\/10.3389\/fimmu.2021.775761.","journal-title":"Front Immunol"},{"issue":"1","key":"6344_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11299-y","volume":"23","author":"S Nasr","year":"2023","unstructured":"Nasr S, Haddad FG, Khazen J, et al. PD-L1 protein expression by combined positive score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience. BMC Cancer. 2023;23(1):817. https:\/\/doi.org\/10.1186\/s12885-023-11299-y.","journal-title":"BMC Cancer"},{"issue":"3","key":"6344_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387(3):217\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2202809.","journal-title":"N Engl J Med"},{"key":"6344_CR32","doi-asserted-by":"publisher","first-page":"107327482199743","DOI":"10.1177\/1073274821997430","volume":"28","author":"K Chen","year":"2021","unstructured":"Chen K, Wang X, Yang L, et al. The anti-PD-1\/PD-L1 immunotherapy for gastric esophageal cancer: a systematic review and meta-analysis and literature review. Cancer Control. 2021;28:1073274821997430. https:\/\/doi.org\/10.1177\/1073274821997430.","journal-title":"Cancer Control"},{"key":"6344_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/clep.S129886","volume":"9","author":"J Kahlert","year":"2017","unstructured":"Kahlert J, Gribsholt SB, Gammelager H, et al. Control of confounding in the analysis phase - an overview for clinicians. Clin Epidemiol. 2017;9:195\u2013204. https:\/\/doi.org\/10.2147\/clep.S129886.","journal-title":"Clin Epidemiol"},{"key":"6344_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133064","author":"G Del Baldo","year":"2022","unstructured":"Del Baldo G, Abbas R, De Ioris MA, et al. The prognostic role of the C-reactive protein and serum lactate dehydrogenase in a pediatric series of bone Ewing sarcoma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14133064.","journal-title":"Cancers (Basel)"},{"key":"6344_CR35","doi-asserted-by":"publisher","first-page":"1124517","DOI":"10.3389\/fonc.2023.1124517","volume":"13","author":"Z Liu","year":"2023","unstructured":"Liu Z, Wang X, Wang J, et al. The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: a multicenter retrospective study. Front Oncol. 2023;13:1124517. https:\/\/doi.org\/10.3389\/fonc.2023.1124517.","journal-title":"Front Oncol"},{"key":"6344_CR36","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.2147\/cmar.S191199","volume":"11","author":"C Mirili","year":"2019","unstructured":"Mirili C, Payda\u015f S, Guney IB, et al. Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study. Cancer Manag Res. 2019;11:3445\u201353. https:\/\/doi.org\/10.2147\/cmar.S191199.","journal-title":"Cancer Manag Res"},{"key":"6344_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111713","author":"DE Meyers","year":"2019","unstructured":"Meyers DE, Stukalin I, Vallerand IA, et al. The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11111713.","journal-title":"Cancers (Basel)"},{"key":"6344_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.952228","volume":"12","author":"X He","year":"2022","unstructured":"He X, Lu M, Hu X, et al. Osteosarcoma immune prognostic index can indicate the nature of indeterminate pulmonary nodules and predict the metachronous metastasis in osteosarcoma patients. Front Oncol. 2022;12:952228. https:\/\/doi.org\/10.3389\/fonc.2022.952228.","journal-title":"Front Oncol"},{"key":"6344_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz027.001","volume":"30","author":"A Varga","year":"2019","unstructured":"Varga A, Bernard-Tessier A, Auclin E, et al. Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. Ann Oncol. 2019;30:i2. https:\/\/doi.org\/10.1093\/annonc\/mdz027.001.","journal-title":"Ann Oncol"},{"issue":"1","key":"6344_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14740\/wjon1179","volume":"10","author":"S Minami","year":"2019","unstructured":"Minami S, Ihara S, Komuta K. Pretreatment lung immune prognostic index is a prognostic marker of chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor. World J Oncol. 2019;10(1):35\u201345. https:\/\/doi.org\/10.14740\/wjon1179.","journal-title":"World J Oncol"},{"issue":"12","key":"6344_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123842","volume":"19","author":"S Rot","year":"2018","unstructured":"Rot S, Taubert H, Bache M, et al. Low HIF-1\u03b1 and low EGFR mRNA expression significantly associate with poor survival in soft tissue sarcoma patients; the proteins react differently. Int J Mol Sci. 2018;19(12):3842.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6344_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00256-022-04244-w","volume":"52","author":"JC Fanburg-Smith","year":"2023","unstructured":"Fanburg-Smith JC, Smith JD, Flemming DJ. Bone and soft tissue tumors: clinicoradiologic-pathologic molecular-genetic correlation of novel fusion spindled, targetable-ovoid, giant-cell-rich, and round cell sarcomas. Skeletal Radiol. 2023;52(3):517\u201340. https:\/\/doi.org\/10.1007\/s00256-022-04244-w.","journal-title":"Skeletal Radiol"},{"issue":"10","key":"6344_CR43","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.devcel.2022.04.003","volume":"57","author":"AG Patel","year":"2022","unstructured":"Patel AG, Chen X, Huang X, et al. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. Dev Cell. 2022;57(10):1226-40.e8. https:\/\/doi.org\/10.1016\/j.devcel.2022.04.003.","journal-title":"Dev Cell"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-06344-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-025-06344-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-06344-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:51:28Z","timestamp":1761742288000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-025-06344-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6344"],"URL":"https:\/\/doi.org\/10.1186\/s13018-025-06344-4","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were approved by Medical Ethics Committee of the West China hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from all adult participants and from legal guardians of minors. Additionally, minors aged 12 years and older provided written assent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"941"}}